Peptide News Digest

#Uae

2 stories

Industry · View digest

Wegovy Pill Launched in UAE on June 3 as Novo's First International Rollout Outside the US

Novo Nordisk launched the Wegovy pill in the United Arab Emirates on June 3, the first country outside the US to make the oral semaglutide tablet available since the January 5 US launch. The UAE rollout used a distribution structure that piggybacks on existing diabetes-channel infrastructure rather than a parallel direct-to-consumer build, and arrived ahead of the UK MHRA approval today. Novo had previously guided to second-half 2026 for international rollouts.

Industry · View digest

Foundayo Reaches UAE Pharmacies May 12: Dubai + Abu Dhabi Coverage at AED 773-1,599 Self-Pay Across Dose Strengths

Eli Lilly's Foundayo (orforglipron) reached UAE pharmacies on May 12 in Abu Dhabi, expanding from the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill. Pricing runs from AED 773/month for the 0.8 mg starter dose to AED 1,599/month for the 17.2 mg highest dose. Abu Dhabi has folded Foundayo into the emirate's broader weight-loss program, signaling government coverage rather than purely self-pay. The launch is one of the first international rollouts since FDA approval April 1; Lilly executives have framed UAE prescribing patterns and patient adherence as an early read on geriatric and Middle East regional patient response.